Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bavarian Nordic To Raise $250m For Phase III RSV Vaccine Study

Self-Funded Trial To Begin Next Year

Executive Summary

The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022

You may also be interested in...



J&J Sets The Pace In Race To $10bn RSV Vaccine Market

Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.

Bavarian Nordic Seeks Partner After RSV Jab Generates Glowing Phase II Data

Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.

Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program

Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel